Tecfidera’s impressive launch hit by supply and reiumbursement problems

June 20 2013 | By Márcio Barrahm duno

Tecfidera, Biogen’s idec of first-line oral treatment for people with relapsing forms of Multiple Sclerosis  approved back in March in the US and EU, is having a very impressive start, selling so well that it’s expected to break the blockbuster barrier by next year according to the The Wall Street Journal. But the demand is such among patients, doctors and pharmacies that supply hasn’t been able to fully satisfy the demand.  Supply chain and manufacturing snags also interfered with distribution, said Biogen’s CEO George Scangos.

View original post 252 more words

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s